Overview

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

Status:
Completed

Trial end date:
2009-12-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the safety and tolerability of Zanamivir using a Rotahaler device presentation to placebo within the Rotahaler presentation and to the Diskhaler device.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Zanamivir